Durability of VEGF Suppression With Intravitreal Aflibercept and Brolucizumab: Using Pharmacokinetic Modeling to Understand Clinical Outcomes

PURPOSE: To investigate whether vascular endothelial growth factor (VEGF)–suppression durations contribute to our understanding of clinical trial outcomes by simulating vitreous molar concentrations (C(vm)) of intravitreal aflibercept (IVT-AFL) and brolucizumab (IVT-BRO) using pharmacokinetic (PK) m...

Descripción completa

Detalles Bibliográficos
Autores principales: Eissing, Thomas, Stewart, Michael W., Qian, Cynthia X., Rittenhouse, Kay D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Association for Research in Vision and Ophthalmology 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8054631/
https://www.ncbi.nlm.nih.gov/pubmed/34003985
http://dx.doi.org/10.1167/tvst.10.4.9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8054631/
https://www.ncbi.nlm.nih.gov/pubmed/34003985
http://dx.doi.org/10.1167/tvst.10.4.9

Ejemplares similares